During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
|Videos|March 30, 2021
A 72-Year-Old Man With Heavily Pretreated, Relapsed/Refractory Multiple Myeloma
Author(s)Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP, presents a case of a 72-year-old man with heavily pretreated relapsed/refractory multiple myeloma and discusses treatment options for patients with this diagnosis who have failed multiple prior lines of therapy.
Advertisement
A 72-Year-Old Man with Heavily Pretreated, R/R Multiple Myeloma
Initial Presentation
- A 72-year-old man diagnosed with multiple myeloma 4.5 years ago returns for routine follow up
- Treatment history:
- Initially treated with VRd for 12 months, followed by lenalidomide maintenance 15 mg daily; stable disease lasting 36 months
- Rechallenged with VRd, stable disease lasting 20 months
- Subsequently switched to KPd, achieved a partial response lasting 15 months
- Started DVd; follow up at 12 months showed M protein increase by 0.5 g/dl; patient continues to feel well
- Currently, 3 months after his last visit, he returns to the clinic complaining of increased muscle weakness, fatigue and bone pain
- PE: new bony tenderness appreciated on ribs, bruising, mild bleeding of the gums
Clinical Workup
- Labs: Hb 8.8 g/dL, calcium 10.2 mg/dL, LDH 160 U/L, creatinine 2.1 mg/dL, albumin 3.0 g/dL, b2 microgloblulin 4.9 mcg/mL, serum M-protein 4.2 g/dL, lambda free light chains 4.1 mg/dL
- HBV negative
- Skeletal survey and MRI revealed stable lytic bone lesions in the left hip, pelvis and L2 vertebrae and new lytic lesions on the ribs 4 and 10 on the left side
- Bone marrow shows 70% plasma cells IgG k
- FISH: t(6;14) (p21;q32) at diagnosis; new del(17p)
- Diagnosis: R-ISS stage II MM
- ECOG 1
Treatment
- Initiated treatment with belantamab mafodotin
Advertisement
Related to this article
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5